Ionctura

ionctura bv, headquartered in geneva, switzerland, was founded in june 2017 as a spin out from merck and funded by m ventures. it is a clinical stage biotechnology company developing a pipeline of next generation, differentiated molecules that are at the forefront of pioneering new therapies for the treatment of cancer. each of ionctura’s programs harness the combined effect of immune-mediated and direct anti-tumour activity and aim to deliver molecules with superior clinical efficacy and safety in oncology. the company’s lead program, ioa-244, will enter the clinic in q1 2020. the study is aimed to clinically demonstrate for the first time that a highly selective pi3kδ inhibition not only drives an immune-mediated response but also a direct anti-tumoural effect in a stratified patient population across multiple solid tumour indications. the company’s second molecule is a novel autotaxin (atx) inhibitor at ind stage for patients with solid tumours burdened with cancer-associated fibro